Deciduous Therapeutics
San Francisco, US · Founded 2018 · Delaware corporation · 8 known investors
Find your way into Deciduous Therapeutics
266 people in our graph share verified history with the Deciduous Therapeutics team — schools, employers, funds. One of them is your warm intro.
Logan Hilleunlockedknows Anil Bhushan · together at University of California, San Francisco (overlapped)
×3knows the team · via University of California, San Francisco
×7knows the team · via Case Western Reserve University
knows the team · via New York University
Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders. The company serves patients with conditions driven by cellular aging and senescence.
Founders & leadership
Deciduous Therapeutics was founded in 2018 by Robin Mansukhani and Anil Bhushan.
RM
Robin MansukhaniinCEO and Co-FounderRobin Mansukhani is CEO and co-founder of Deciduous Therapeutics, which develops immunomodulatory therapies targeting senescent cells for age-related diseases. He previously co-founded and led Alzeca Biosciences, a CNS diagnostic imaging company, and has worked in early-stage venture capital and investment banking; he holds a B.S. in Biochemistry from Case Western Reserve University.
AB
Anil BhushaninScientific FounderAnil Bhushan is a Professor of Medicine at UCSF with training from the Salk Institute and Institut Curie, and an independent laboratory background at UCLA. He studies stromal immunology and tissue microenvironments, with research focused on beta cell biology and the role of chromatin regulation in endocrine function, and co-founded Deciduous Therapeutics in 2019 to develop immunological therapies targeting senescent cells.
Board
DM
Investors · 8
age1San Francisco · $500K – $4M
Bold Capital PartnersSanta Monica
Cornucopian Capital ManagementMontclair
CRV (Charles River Ventures)Bay Area · $250K – $5M
Owl Capitalvia Jennifer Scott Fonstad · inferred
quadraScope Venture FundBoston
Axial VCreportedSan Francisco · $100K – $5M
Mana VenturesreportedEstero
Reported raises · per SEC filings
Form D private placements$5.8M disclosed across 1 round · 2019
▶$5.8MraisedJul 2019 · 10 investors · BiotechnologyRule 506(b)
▶$5.8MraisedJul 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robin MansukhaniExecutive Officer, Director
- Dylan MorrisDirector
- Anil BhushanDirector
- Offering amount
- $6.5M
- Amount sold
- $5.8M
- Minimum investment
- $10K
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapDialectic Therapeutics7 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Dewpoint Therapeutics5 shared keywordsDewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms. Its discovery engine combines biology, chemistry, proprietary datasets, and AI to pursue therapies for complex diseases, including previously undruggable targets.
Edgewise Therapeutics4 shared keywordsEdgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
Celldex Therapeutics, Inc.4 shared keywordsCelldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
Eli Lilly4 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Kite Pharma3 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Preqin3 shared keywordsPreqin provides a data and intelligence platform for investment teams, M&A professionals, and corporate development teams to source, evaluate, and value private company investments through integrated asset, fund, and performance data.
Companies competing with Deciduous Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Deciduous Therapeutics do?
- Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders. The company serves patients with conditions driven by cellular aging and senescence.
- Who founded Deciduous Therapeutics?
- Deciduous Therapeutics was founded by Robin Mansukhani, Anil Bhushan in 2018.
- Who are Deciduous Therapeutics's investors?
- Deciduous Therapeutics's investors include age1, Bold Capital Partners, Cornucopian Capital Management, CRV (Charles River Ventures), Owl Capital, quadraScope Venture Fund, Axial VC, Mana Ventures.
- How much funding has Deciduous Therapeutics raised?
- Deciduous Therapeutics has disclosed $5.8M raised across 1 round.
- Where is Deciduous Therapeutics headquartered?
- Deciduous Therapeutics is headquartered in San Francisco, US.